Addex Reports ADX71441 Reduces Alcohol Intake in a Preclinical Model of Alcohol Binge Drinking

Addex Updates Financial Guidance for 2012

Addex Therapeutics raises $10 million in a Private Placement to International Institutional Investors

Addex Scientists Present New Data on Oral Small Molecule Programs Targeting GPCR at the Society for Neuroscience 2012 Meeting

Addex and Collaborators Awarded Swiss CTI Grant to Develop Allosteric Modulators for Neurodegenerative and Psychiatric Diseases

Addex mGluR4 Allosteric Modulator Effective in Multiple Sclerosis Model

Addex Partner Doses First Patient in Phase 2 Clinical Study of ADX71149 for the Treatment of Major Depressive Disorder Patients with Anxiety Symptoms

Addex Therapeutics First Half 2012 Financial results

Addex Therapeutics First Half 2012 Financial Results Next Wednesday

Addex Announces the Publication of Positive Data on the Efficacy of mGluR4 Positive Allosteric Modulator in Parkinson’s Disease Pre-Clinical Models